ATE236630T1 - Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten - Google Patents

Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten

Info

Publication number
ATE236630T1
ATE236630T1 AT96901018T AT96901018T ATE236630T1 AT E236630 T1 ATE236630 T1 AT E236630T1 AT 96901018 T AT96901018 T AT 96901018T AT 96901018 T AT96901018 T AT 96901018T AT E236630 T1 ATE236630 T1 AT E236630T1
Authority
AT
Austria
Prior art keywords
pct
sclareolids
treatment
excessive cell
cell growth
Prior art date
Application number
AT96901018T
Other languages
English (en)
Inventor
Pierre Braquet
Denis Bigg
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of ATE236630T1 publication Critical patent/ATE236630T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Furan Compounds (AREA)
AT96901018T 1995-01-04 1996-01-04 Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten ATE236630T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9500024.6A GB9500024D0 (en) 1995-01-04 1995-01-04 Treatment of excessive cell proliferation disorders
PCT/FR1996/000015 WO1996020704A1 (fr) 1995-01-04 1996-01-04 Traitement d'affections caracterisees par une proliferation excessive des cellules avec sclareolide

Publications (1)

Publication Number Publication Date
ATE236630T1 true ATE236630T1 (de) 2003-04-15

Family

ID=10767544

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96901018T ATE236630T1 (de) 1995-01-04 1996-01-04 Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten

Country Status (9)

Country Link
US (1) US5906993A (de)
EP (1) EP0793492B1 (de)
JP (1) JPH10511673A (de)
AT (1) ATE236630T1 (de)
AU (1) AU4530796A (de)
CA (1) CA2209276A1 (de)
DE (1) DE69627298D1 (de)
GB (1) GB9500024D0 (de)
WO (1) WO1996020704A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150381A (en) 1998-06-09 2000-11-21 R.J. Reynolds Tobacco Company Methods of treating microbial infection and therapeutic formulations therefor
DK1272154T3 (da) 2000-04-04 2005-01-31 Color Access Inc Præparat til forbedring af hudlipidbarrierefunktionen
US7588759B2 (en) * 2004-12-17 2009-09-15 Avoca, Inc. Compositions comprising sclareol or derivatives thereof and uses thereof
EP2789369B1 (de) * 2013-04-14 2018-06-06 Symrise AG Eine Zubereitung zur Aufhellung von Haut und Haaren
EP3097905B1 (de) * 2015-05-28 2020-11-04 Symrise AG Kosmetische zubereitungen
EP4486314A1 (de) * 2022-03-01 2025-01-08 ISP Investments LLC Sclareol oder sclareolid zur verbesserung der kopfhauterkrankungen und des haarwachstums

Also Published As

Publication number Publication date
EP0793492A1 (de) 1997-09-10
DE69627298D1 (de) 2003-05-15
US5906993A (en) 1999-05-25
CA2209276A1 (fr) 1996-07-11
GB9500024D0 (en) 1995-03-01
JPH10511673A (ja) 1998-11-10
AU4530796A (en) 1996-07-24
EP0793492B1 (de) 2003-04-09
WO1996020704A1 (fr) 1996-07-11

Similar Documents

Publication Publication Date Title
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE154758T1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DK0571415T3 (da) Biologisk nedbrydelige og biologisk absorberbare ledekanaler til anvendelse ved behandling og regenerering af nerver
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
DK0880350T3 (da) Behandling af dissemineret sklerose
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
EP1098642A4 (de) Verfahren zur behandlung von zustanden moduliert durch lactosylceramiden
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE236630T1 (de) Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten
ATE191342T1 (de) Verwendung von riluzol zur behandlung mitochondrialer erkrankungen
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69630055D1 (de) Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation
ATE239458T1 (de) Verwendung von selegilin zur behandlung von epileptischen erkrankungen
ATE213634T1 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69428797D1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE69620394D1 (de) Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties